Wild-type MIC distributions and epidemiological cutoff values for amphotericin B, flucytosine, and itraconazole and Candida spp. as determined by CLSI broth microdilution

Journal of Clinical Microbiology

Volumn 50, Issue 6, 2012, Pages 2040-2046

  Pfaller, M A ^a   Espinel Ingroff, A ^b   Canton, E ^c   Castanheira, M ^a   Cuenca Estrella, M ^d   Diekema, D J ^e   Fothergill, A ^f   Fuller, J ^g   Ghannoum, M ^h   Jones, R N ^a   Lockhart, S R ⁱ   Martin Mazuelos, E ^j   Melhem, M S C ^k   Ostrosky Zeichner, L ^l   Pappas, P ^m   Pelaez, T ⁿ   Peman, J ^c   Rex, J ^o   Szeszs, M W ^p  

^a JMI LABORATORIES   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^c HOSPITAL UNIVERSITARIO LA FE   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITY OF IOWA   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

ⁱ CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^j HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^k Adolfo Lutz Institute Public Health Reference Center   (Brazil)

^l UNIVERSITY OF TEXAS   (United States)

^m UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁿ HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^o ASTRAZENECA   (United Kingdom)

^p INSTITUTO ADOLFO LUTZ   (Brazil)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCYTOSINE; ITRACONAZOLE;

ANALYTICAL PARAMETERS; ARTICLE; BACTERIUM ISOLATE; BRAZIL; BROTH DILUTION; CANADA; CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLAVISPORA LUSITANIAE; CLINICAL BREAKPOINT VALUE; CLINICAL LABORATORY; CONTROLLED STUDY; DRUG MONITORING; DRUG SENSITIVITY; EPIDEMIOLOGICAL CUTOFF VALUE; EUROPE; MICROBIOLOGICAL PARAMETERS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PRIORITY JOURNAL; STANDARD; UNITED STATES;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BRAZIL; CANADA; CANDIDA; CANDIDIASIS; EUROPE; FLUCYTOSINE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; UNITED STATES;

CANDIDA; CANDIDA ALBICANS; CANDIDA DUBLINIENSIS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

EID: 84862098899     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.00248-12     Document Type: Article

References (41)

1. Arendrup MC, Kahlmeter G, Rodriguez-Tudela JL, Donnelly JP. 2009. Breakpoints for susceptibility testing should not divide wild-type distributions of important target species. Antimicrob. Agents Chemother. 53:1628-1629.
2. Barchiesi F, Arzeni D, Caselli F, Scalise G. 2000. Primary resistance to flucytosine among clinical isolates of Candida spp. J. Antimicrob. Chemother. 45:408-409. (Pubitemid 30139259)
3. British Society for Mycopathology. 1984. Laboratory methods for flucytosine (5-fluorocytosine). Report of a working group of the British Society for Mycopathology. J. Antimicrob. Chemother. 14:1-8.
4. Clinical and Laboratory Standards Institute. 2008. M27-A3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Clinical and Laboratory Standards Institute. 2008. M27-S3. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd informational supplement. Clinical and Laboratory Standards Institute, Wayne, PA.
6. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, Rodriguez-Tudela JL. 2001. Flucytosine primary resistance in Candida species and Cryptococcus neoformans. Eur. J. Clin. Microbiol. Infect. Dis. 20:276-279. (Pubitemid 32477248)
7. Diekema DJ, et al. 2009. In vitro activity of seven systemically active antifungal agents against a large global collection of rare Candida species as determined by CLSI broth microdilution methods. J. Clin. Microbiol. 47:3170-3177.
8. Dodgson AR, Dodgson KJ, Pujol C, Pfaller MA, Soll DR. 2004. Clade-specific flucytosine resistance is due to a single nucleotide change in the FUR1 gene of Candida albicans. Antimicrob. Agents Chemother. 48:2223-2227. (Pubitemid 38691622)
9. Edlind TD, Katiyar SK. 2010. Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob. Agents Chemother. 54:4733-4738.
10. Florent M, et al. 2009. Nonsense and missense mutations in FCY2 and FCY1 genes are responsible for flucytosine resistance and flucytosine-fluconazole cross-resistance in clinical isolates of Candida lusitaniae. Antimicrob. Agents Chemother. 53:2982-2990.
11. Hoban DJ, Zhanel GG, Karlowsky JA. 1999. In vitro susceptibilities of Candida and Cryptococcus neoformans isolates from blood cultures of neutropenic patients. Antimicrob. Agents Chemother. 43:1463-1464. (Pubitemid 29259344)
12. Hope WW, Tabernero L, Denning DW, Anderson MJ. 2004. Molecular mechanisms of primary resistance to flucytosine in Candida albicans. Antimicrob. Agents Chemother. 48:4377-4386. (Pubitemid 39434901)
13. Kahlmeter G, et al. 2003. European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria. J. Antimicrob. Chemother. 52:145-148. (Pubitemid 36986868)
14. Kao AS, et al. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170. (Pubitemid 30265634)
15. Law D, Moore CB, Denning DW. 1997. Amphotericin B resistance testing of Candida spp.: a comparison of methods. J. Antimicrob. Chemother. 40:109-112. (Pubitemid 27341641)
16. Martinez-Suarez JV, Rodriguez-Tudela JL. 1995. Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain. Antimicrob. Agents Chemother. 39:1512-1516.
17. McManus BA, Moran GP, Higgins JA, Sullivan DJ, Coleman DC. 2009. ASer29Leu substitution in the cytosine deaminase Fca1p is responsible for clade-specific flucytosine resistance in Candida dubliniensis. Antimicrob. Agents Chemother. 53:4678-4685.
18. Mora-Duarte J, et al. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029. (Pubitemid 35461658)
19. Ostrosky-Zeichner L, et al. 2003. Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154. (Pubitemid 37229571)
20. Pakyz AL, Gurgle HE, Oinonen MJ. 2011. Antifungal use in hospitalized adults in U.S. academic health centers. Am. J. Health Syst. Pharm. 68:415-418.
21. Pappas PG, et al. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
22. Park BJ, et al. 2006. Evaluation of amphotericin B interpretive breakpoints for Candida bloodstream isolates by correlation with therapeutic outcome. Antimicrob. Agents Chemother. 50:1287-1292.
23. Pfaller MA, et al. 2011. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn. Microbiol. Infect. Dis. 70:330-343.
24. Pfaller MA, et al. 2010. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist. Updat. 13:180-195.
25. Pfaller MA, et al. 2011. Wild-type MIC distributions and epidemiological cutoff values for posaconazole and voriconazole and Candida spp. as determined by 24-hour CLSI broth microdilution. J. Clin. Microbiol. 49:630-637.
26. Pfaller MA, et al. 2010. Wild-type MIC distributions and epidemiological cutoff values for the echinocandins and Candida spp. J. Clin. Microbiol. 48:52-56.
27. Pfaller MA, et al. 2005. In vitro susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species to itraconazole: global survey of 9,359 isolates tested by Clinical and Laboratory Standards Institute broth microdilution methods. J. Clin. Microbiol. 43:3807-3810. (Pubitemid 41129665)
28. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011. Triazole and echinocandin wild-type MIC distributions with epidemiological cutoff values for six uncommon species of Candida. J. Clin. Microbiol. 49:3800-3804.
29. Pfaller MA, Diekema D. 2010. Wild-type MIC distributions and epidemiological cutoff values for fluconazole and Candida: time for new clinical breakpoints? Curr. Fungal Infect. Rep. 4:168-174.
30. Pfaller MA, et al. 2011. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria. Drug Resist. Updat. 14:164-176.
31. Pfaller MA, et al. 2002. In vitro activities of 5-fluorocytosine against 8,803 clinical isolates of Candida spp.: global assessment of primary resistance using National Committee for Clinical Laboratory Standards susceptibility testing methods. Antimicrob. Agents Chemother. 46:3518-3521. (Pubitemid 35192920)
32. Pujol C, Pfaller MA, Soll DR. 2004. Flucytosine resistance is restricted to a single genetic clade of Candida albicans. Antimicrob. Agents Chemother. 48:262-266. (Pubitemid 38040206)
33. Rex JH, et al. 1994. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N. Engl. J. Med. 331:1325-1330. (Pubitemid 24347001)
34. Rex JH, Pfaller MA. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989. (Pubitemid 35178316)
35. Rex JH, Pfaller MA, Barry AL, Nelson PW, Webb CD. 1995. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group. Antimicrob. Agents Chemother. 39:40-44.
36. Rex JH, et al. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards. Clin. Infect. Dis. 24:235-247. (Pubitemid 127774263)
37. Rex JH, et al. 2001. Antifungal susceptibility testing: practical aspects and current challenges. Clin. Microbiol. Rev. 14:643-658. (Pubitemid 32979625)
38. Turnidge J, Kahlmeter G, Kronvall G. 2006. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin. Microbiol. Infect. 12:418-425.
39. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin. Microbiol. Rev. 20:391-408. (Pubitemid 47175010)
40. Vandeputte P, et al. 2011. Molecular mechanisms of resistance to 5-fluorocytosine in laboratory mutants of Candida glabrata. Mycopathologia 171:11-21.
41. Walsh TJ, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360. (Pubitemid 351265310)